Vireo Growth (VREOF) Liabilities from Discontinued Operations (2020 - 2025)

Vireo Growth (VREOF) reported Liabilities from Discontinued Operations of 89334872.0 for Q3 2025, up 1.02% on a YoY basis from 88437021.0 in Q3 2024, and little changed sequentially from 89379390.0 in Q2 2025.

Vireo Growth (VREOF) Liabilities from Discontinued Operations (2020 - 2025) Analysis & Trends

Vireo Growth (VREOF) has 6 years of Liabilities from Discontinued Operations data on file, last reported at 89334872.0 in Q3 2025.

  • For the quarter ending Q3 2025, Liabilities from Discontinued Operations rose 1.02% year-over-year to 89334872.0; the trailing twelve-month figure through Sep 2025 stood at 89334872.0 (up 1.02% YoY), and the FY2024 full-year result was 89387203.0, up 1.2% from the prior year.
  • Liabilities from Discontinued Operations was little changed at 89334872.0 in Q3 2025, from 89379390.0 in the prior quarter.
  • In the past five years, Liabilities from Discontinued Operations ranged from a high of 89387203.0 in Q4 2024 to a low of 116803.0 in Q3 2021.
  • A 5-year average of 58887381.31 and a median of 81925789.0 in 2023 frame the typical range for Liabilities from Discontinued Operations.
  • Across the five-year window, Liabilities from Discontinued Operations jumped 6592.16% in 2023 and advanced 1.02% in 2025, its largest moves.
  • Tracing VREOF's Liabilities from Discontinued Operations over 5 years: stood at 116803.0 in 2021, then jumped by 1029.98% to 1319847.0 in 2022, then jumped by 6592.16% to 88326323.0 in 2023, then grew by 1.2% to 89387203.0 in 2024, then retreated by 0.06% to 89334872.0 in 2025.
  • Business Quant data shows VREOF's Liabilities from Discontinued Operations at 89334872.0 in Q3 2025, 89379390.0 in Q2 2025, and 89351157.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn

Historic Data

Download Data
DateValue
Sep 30, 2025 89.33 Mn
Sep 30, 2025 89.33 Mn
Jun 30, 2025 89.38 Mn
Jun 30, 2025 89.38 Mn
Mar 31, 2025 89.35 Mn
Mar 31, 2025 89.35 Mn
Dec 31, 2024 89.39 Mn
Dec 31, 2024 89.39 Mn
Sep 30, 2024 88.44 Mn
Sep 30, 2024 88.44 Mn
Jun 30, 2024 88.41 Mn
Jun 30, 2024 88.41 Mn
Mar 31, 2024 88.37 Mn
Mar 31, 2024 88.37 Mn
Dec 31, 2023 88.33 Mn
Dec 31, 2023 88.33 Mn
Sep 30, 2023 75.44 Mn
Sep 30, 2023 75.44 Mn
Jun 30, 2023 75.15 Mn
Jun 30, 2023 75.15 Mn